Immunotherapy News and Research RSS Feed - Immunotherapy News and Research

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
Two autologous stem-cell transplants improve survival of children with high-risk neuroblastoma

Two autologous stem-cell transplants improve survival of children with high-risk neuroblastoma

Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be free of cancer three years later than patients who underwent a single transplant, a Phase 3 clinical trial has found. [More]
Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute. [More]
Combination immunotherapy may be better than one to combat metastatic melanoma

Combination immunotherapy may be better than one to combat metastatic melanoma

A new metastatic melanoma study suggests that a combination of two immunotherapies may be better than one. [More]
Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting. [More]
Personlized exercise pattern may help reduce neuropathic symptoms of chemotherapy

Personlized exercise pattern may help reduce neuropathic symptoms of chemotherapy

Researchers at the University of Rochester Wilmot Cancer Institute discovered something simple and inexpensive to reduce neuropathy in hands and feet due to chemotherapy--exercise. [More]
Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

A significant proportion of lung cancer patients also have autoimmune disease, which may make them unsuitable for increasingly popular immunotherapy treatments, a team of researchers at UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center has found. [More]
Gene dysregulation makes immune therapies less effective against metastatic melanoma

Gene dysregulation makes immune therapies less effective against metastatic melanoma

Patients who don't respond to treatments that use their own immune cells to destroy tumors, called tumor infiltrating lymphocytes, share changes in mechanisms that switch genes on or off in those cells, according to study results presented at the annual meeting of the American Society for Clinical Oncology on June 4 in Chicago. [More]
Novel treatment combination helps combat hard-to-treat pediatric neuroblastoma

Novel treatment combination helps combat hard-to-treat pediatric neuroblastoma

For seven months, three-year-old Emil Abbasov underwent chemotherapy to fight the tangerine-sized, cancerous tumor growing in his abdomen. But each time, the tumor resisted harder. Each time, he felt more side effects. [More]
Novel drug atezolizumab harnesses immune system to shrink tumors in advanced bladder cancer

Novel drug atezolizumab harnesses immune system to shrink tumors in advanced bladder cancer

A new drug that harnesses the immune system to attack tumors is highly effective against advanced bladder cancer, according to the results of an international clinical trial to be presented June 5 at the annual meeting of the American Society for Clinical Oncology. [More]
Nivolumab drug shows better response rate in metastatic bladder cancer patients

Nivolumab drug shows better response rate in metastatic bladder cancer patients

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center. [More]
Stimulating STING pathway to provoke life-extending immune response shows promise in AML

Stimulating STING pathway to provoke life-extending immune response shows promise in AML

A protein known as STING plays a crucial role in the immune system's ability to "sense" cancer by recognizing and responding to DNA from tumor cells. Injection of compounds that activate the STING pathway directly into solid tumors in mice has been shown in prior studies to result in very potent anti-tumor immune responses. [More]
Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

Neuroblastoma tumors shrank, some dramatically, in 80 percent of newly diagnosed, young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody. The immunotherapy agent was produced on the St. Jude Children's Research Hospital campus where the study is still underway. [More]
Nivolumab and ipilimumab combination could lead to effective treatment options for SCLC patients

Nivolumab and ipilimumab combination could lead to effective treatment options for SCLC patients

Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that has no effective treatment options. [More]
TxCell, LIED collaborate to develop CAR-Treg-based cellular immunotherapy for bullous pemphigoid

TxCell, LIED collaborate to develop CAR-Treg-based cellular immunotherapy for bullous pemphigoid

TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells to treat severe chronic inflammatory and autoimmune diseases, today announces the signature of a strategic R&D collaboration agreement with the Lübeck Institute of Experimental Dermatology, a leading institution in the field of translational research on skin blistering diseases, part of the University of Lübeck in Germany. [More]
Experts urge cancer researchers to use old, obese mice for preclinical immunotherapy studies

Experts urge cancer researchers to use old, obese mice for preclinical immunotherapy studies

Researchers should include laboratory mice that are old and obese in their studies of immunotherapy treatments for cancer, according to a review article by Saint Louis University scientists. [More]
Brain scan combined with long-term memory test could help early Alzheimer's diagnosis

Brain scan combined with long-term memory test could help early Alzheimer's diagnosis

People with Alzheimer's disease could benefit from earlier diagnosis if a long-term memory test combined with a brain scan were carried out, a study suggests. [More]
Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

An immune-based therapy developed at Roswell Park Cancer Institute is moving forward with its third clinical trial. The early-stage clinical trial will assess whether SurVaxM — a cancer vaccine developed at Roswell Park — is a safe and effective treatment option for patients with multiple myeloma, a rare type of blood cancer. [More]
Oncologists combine two different types of immunotherapy to successfully treat metastatic melanoma

Oncologists combine two different types of immunotherapy to successfully treat metastatic melanoma

Oncologists at the Fred Hutchinson Cancer Research Center have successfully treated a patient with metastatic melanoma by combining two different types of immunotherapy. Cassian Yee and colleagues describe their approach in a paper, "Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient," that will be published online May 30 in The Journal of Experimental Medicine. [More]
Oncologists to present latest research findings at ASCO annual meeting

Oncologists to present latest research findings at ASCO annual meeting

Oncologists from NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine will discuss their latest research findings at the American Society for Clinical Oncology annual meeting, June 3-7 in Chicago. [More]
Certain HLA genes may increase ovarian cancer risk in women

Certain HLA genes may increase ovarian cancer risk in women

Researchers in the Center for Immunotherapy at Roswell Park Cancer Institute have evaluated the human leukocyte antigen (HLA), a group of genes that help regulate the body's immune system, for underlying differences in ovarian cancer patients' response to therapy. [More]
Advertisement
Advertisement